BCA
GBT

Berman Capital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Berman Capital Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4K Buy
+175
New +$5.14K ﹤0.01% 1536
2020
Q3 		– Sell
-15
Closed – – 1835
2020
Q2 		$0 Buy
+15
New +$1.03K ﹤0.01% 1891

Other funds holding GBT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Berman Capital Advisors's GBT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q3 2021: 175 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #1536 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in GBT as recently as Q2 2020.

Berman Capital Advisors first reported a position in GBT in Q2 2020 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold GBT as of Q3 2021.

  • Berman Capital Advisors held 175 shares of Global Blood Therapeutics, Inc. worth $4K as of Q3 2021.
  • Global Blood Therapeutics, Inc. was a new Berman Capital Advisors position in Q3 2021.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1536 holding.
  • Berman Capital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.